RET and non-small cell lung carcinoma: Insignificant actions of multi-targeted TKIs in RET-rearrangements characterized NSCLC, have gradually switched the attention to the next generation, RET-selective inhibitors, such as RXDX-105, BLU-667, and LOXO-292.